focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVerici Dx Regulatory News (VRCI)

Share Price Information for Verici Dx (VRCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.25
Bid: 8.00
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 0.50 (6.25%)
Open: 8.25
High: 8.25
Low: 8.25
Prev. Close: 8.25
VRCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Correction: Holding(s) in Company

1 Dec 2022 18:07

RNS Number : 3453I
Verici Dx PLC
01 December 2022
 

This is a correction to the announcement published on 16 March 2022 at 15:33. The resultant total number of voting rights held in issuer was stated as 8,000,000 (4.70% of the total voting rights) rather than the correct resultant voting rights number of 9,239,660 (5.43% of the total voting rights). The full corrected announcement is as per below, also with an amended 'date on which the issuer was notified', being 1 December 2022. All other information remains unchanged.

 

TR-1: Standard form for notification of major holdings - amendment*

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Verici DX plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Unicorn Asset Management Limited

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

Unicorn AIM VCT plc

City and country of registered office (if applicable)

Newton Abbot, United Kingdom

5. Date on which the threshold was crossed or reachedvi:

14 March 2022

6. Date on which issuer notified (DD/MM/YYYY):

01 December 2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

5.43%

5.43%

9,239,660

Position of previous notification (if

applicable)

3.17%

3.17%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares GB00BM8HZD43

9,239,660

5.43%

SUBTOTAL 8. A

9,239,660

5.43%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Figures are based on total voting rights of 170,319,245

 

\* This is an amendment to the TR1 sent on 16/03/2022 which stated that the % of TVR had moved from 3.17% to 4.70%.

 

Place of completion

Unicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse Square, London, EC1M 6AU

Date of completion

16 March 2022

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBRBDDCSGDGDB
Date   Source Headline
5th Sep 20227:00 amRNSNotice of Results
2nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20224:35 pmRNSPrice Monitoring Extension
27th Jun 20223:17 pmRNSResult of AGM and voting results
24th Jun 20227:00 amRNSHolding(s) in Company
20th Jun 20227:30 amRNSDistribution of Verici Dx shares by EKF
16th Jun 20227:00 amRNSInvestor Presentation
15th Jun 202210:57 amRNSCEO Video Interview
14th Jun 20229:00 amRNSFurther data from Tuteva™ validation study
9th Jun 20227:00 amRNSCommercial Team Appointments
25th May 202212:00 pmRNSPosting of Annual Report & Accounts
19th May 20227:00 amRNSFinal Results
12th May 20227:00 amRNSResults of Tuteva™ clinical validation study
1st Apr 20227:00 amRNSClinical Validation Study Update
23rd Mar 20226:12 pmRNSHolding(s) in Company
21st Mar 20227:00 amRNSHolding(s) in Company
18th Mar 20225:13 pmRNSHolding(s) in Company
16th Mar 20223:33 pmRNSHolding(s) in Company
15th Mar 20224:34 pmRNSHolding(s) in Company
11th Mar 20229:30 amRNSClose of Subscription and Fundraise Update
4th Mar 20224:13 pmRNSResult of Fundraise
4th Mar 202212:20 pmRNSClose of Accelerated Bookbuild
4th Mar 20227:10 amRNSProposed Fundraise
15th Feb 20227:00 amRNSSuccessful completion of analytical validation
26th Jan 20224:28 pmRNSNet Asset Value(s)
14th Jan 20227:00 amRNSInvestor Presentation
12th Jan 20222:00 pmRNSProgress and strategy update
6th Jan 20227:00 amRNSClarava™ and Tuteva™ complete testing requirements
5th Jan 20227:00 amRNSCollaboration with Illumina
4th Jan 20227:00 amRNSGrant of two CPT Codes by AMA
17th Dec 20211:19 pmRNSHolding(s) in Company
8th Nov 20217:00 amRNSLaunch of Barbara T. Murphy Endowed Lectureship
1st Nov 20217:00 amRNSLaunch of Career Development Research Grant
13th Sep 20217:01 amRNSLorenzo Gallon, MD, Appointed as Chair of S.A.B
13th Sep 20217:00 amRNSHalf-year Report
31st Aug 20217:00 amRNSPatient enrolment completed
19th Aug 20217:00 amRNSAppointment of Non-executive Director
27th Jul 20217:00 amRNSAcceptance to CLIA Program
20th Jul 20217:00 amRNSFirst European Clinical Trial Site Initiated
1st Jul 20214:56 pmRNSDirectorate Change
24th Jun 20217:00 amRNSNon-executive Director receives award
26th May 20214:41 pmRNSSecond Price Monitoring Extn
26th May 20214:35 pmRNSPrice Monitoring Extension
19th May 20213:14 pmRNSResult of AGM
5th May 20217:00 amRNSNotice of Change of AGM Venue
29th Apr 20217:00 amRNSLease signed for laboratory
14th Apr 20217:01 amRNSMTA secured to assess CTOT-19 samples
14th Apr 20217:00 amRNSFinal Results
13th Apr 20212:06 pmRNSSecond Price Monitoring Extn
13th Apr 20212:01 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.